AN ACT Relating to coverage for HIV antiviral drugs;
Summary
SB 6183 requires health plans issued or renewed on or after January 1, 2027, to cover all FDA-approved HIV antiviral drugs without prior authorization, step therapy, or other utilization management protocols. The bill also provides that if the FDA has approved therapeutic equivalents for an HIV prevention or treatment drug, a plan does not have to cover every equivalent version without utilization management so long as at least one therapeutically equivalent version is covered without those restrictions.
The measure amends Washington insurance law governing health plans and medical insurance coverage, including plans offered by insurers and certain plans otherwise subject to state insurance requirements. It creates a new section in the insurance code and updates existing RCW provisions to ensure HIV antiviral medications are treated as a required covered benefit under the specified conditions. The practical effect is to limit insurer tools that can delay or steer treatment for HIV medications, while still allowing some formulary management where multiple equivalent products exist.
Impact
The bill expands mandated coverage in Washington’s health insurance laws by requiring plans to cover FDA-approved HIV antiviral drugs without prior authorization, step therapy, or similar utilization controls for policies issued or renewed on or after January 1, 2027. It affects health carriers, insurers, and enrollees in regulated medical insurance plans, and it may increase access to HIV prevention and treatment medications while reducing administrative barriers and potential out-of-pocket delays for patients.
Sentiment
The bill appears to have had strong bipartisan support and little visible opposition. It passed the Senate committee unanimously, cleared the Senate 48-0, passed the House committee unanimously, and then passed the House 91-1. That voting pattern suggests broad agreement that improving access to HIV antiviral drugs is a public health priority.
Contention
There is little evidence of major controversy in the available record. The only substantive policy issue reflected in the text is the balance between access and insurer management: the bill eliminates prior authorization and step therapy for HIV antiviral drugs, but preserves some flexibility for plans when FDA-approved therapeutically equivalent versions exist. Any contention would likely center on insurer cost-control and formulary management concerns versus patient access and treatment adherence, though the votes indicate those concerns did not generate significant opposition.